BENGALURU/NEW YORK — US drug maker Pfizer, which has been considering splitting into two companies for more than two years, said on Monday it would not do so because the move would not create any shareholder value.Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split later if "factors materially change at some point in the future". Pfizer said on Monday the decision would not affect its 2016 financial forecast.The decision not to create two publicly traded companies follows the collapse of its planned $160bn acquisition of Allergan after a change in tax law took away the tax benefits of the deal.Investors were expecting the company to step back from the split, Sanford Bernstein analyst Tim Anderson said."The company seems likely to leave open its option for a future split-up, but more immediately, it may continue hunting for M&A (merger and acquisitions) targets," Anderson wrote.The pharma giant’s shares were down 1.2...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.